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Abstract
Understanding the genetic basis of disease-related phenotypes, such as cancer susceptibility, is crucial for the advancement of
personalized medicine. Although most cancers are somatic in origin, a small number of transmissible cancers have been docu-
mented. Two such cancers have emerged in the Tasmanian devil (Sarcophilus harrisii) and now threaten the species with extinction.
Recently, casesof natural tumor regression in Tasmanian devils infectedwith the clonally contagious cancer have beendetected. We
used whole-genome sequencing and FST-based approaches to identify the genetic basis of tumor regression by comparing the
genomes of seven individuals that underwent tumor regression with those of three infected individuals that did not. We found three
highly differentiated candidate genomic regions containing several genes related to immune response and/or cancer risk, indicating
that the genomic basis of tumor regression was polygenic. Within these genomic regions, we identified putative regulatory variation
in candidate genes but no nonsynonymous variation, suggesting that natural tumor regression may be driven, at least in part, by
differential host expression of key loci. Comparative oncology can provide insight into the genetic basis of cancer risk, tumor
development, and thepathogenicityof cancer, particularlydue toour limitedability tomonitornatural, untreated tumorprogression
in human patients. Our results support the hypothesis that host immune response is necessary for triggering tumor regression,
providing candidate genes that may translate to novel treatments in human and nonhuman cancers.
Key words: genotype–phenotype, cancer, genomics, adaptation.
Introduction
Identifying the genetic basis of complex phenotypes is a cen-
tral goal of modern biology because 1) many fundamental
aspects of evolution, such as pleiotropy (Wagner and Zhang
2011), result from the genotype–phenotype relationship
(Stadler et al. 2001; Hansen 2006); 2) our ability to ultimately
predict evolution depends on understanding these
evolutionary dynamics; and 3) characterizing the genetic basis
of complex traits, particularly disease-related traits such as
cancer risk (Altshuler et al. 2008; Saadatpour et al. 2015), is
of critical importance for conservation and medicine (Harold
et al. 2009; Daub et al. 2013; Albert and Kruglyak 2015;
Campbell et al. 2017; Margres et al. 2018). Indeed, under-
standing the genotype–phenotype relationship is crucial for
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both assessing disease risk and developing personalized pre-
vention and treatment (Katsios and Roukos 2010; Weller et al.
2010; Chin et al. 2011; Freedland 2018). Genomic advances
have enabled the identification of loci associated with onco-
genesis, tumor progression, and even cancer regression and
spontaneous remission (Phan et al. 2003; Yard et al. 2016;
Garcia-Hernandez et al. 2017; Tran et al. 2017; Kumar-Sinha
and Chinnaiyan 2018). Comparative oncology should provide
insight into the genetic basis of cancer risk, tumor develop-
ment, and the pathogenicity of human cancers, particularly
due to our limited ability to monitor natural, untreated tumor
progression in human patients for obvious ethical considera-
tions (Khanna et al. 2006; Schiffman and Breen 2015;
Millanta et al. 2016).
Most cancers are somatic in origin, but a few transmissible
cancers have been documented (reviewed in Ostrander et al.
2016). Such cancers are rare, with the only natural cases
found in dogs (canine transmissible venereal tumor or
CTVT; Murgia et al. 2006), bivalves (Metzger et al. 2016),
and the Tasmanian devil (devil facial tumor disease or DFTD;
Pearse and Swift 2006; Pye et al. 2016). Yet within these
species, six transmissible cancers have recently been discov-
ered (i.e., several in bivalves and a second in Tasmanian devils;
Metzger et al. 2016; Pye et al. 2016), suggesting that these
types of cancers may be more common than previously
thought. Unlike dogs and bivalves, the Tasmanian devil
(Sarcophilus harrisii) is threatened with extinction by the emer-
gence of two clonally transmissible cancers (Hawkins et al.
2006; Murchison et al. 2012; Pye et al. 2016; Stammnitz
et al. 2018; Storfer et al. 2018). Devil facial tumor disease 1
and 2 (DFT1 and DFT2, respectively) are contagious tumor cell
lines and spread via biting, which is common during social
interactions (Hamede et al. 2013). DFT1 was first discovered
in northeastern Tasmania in 1996 and has since spread more
than 80% of the way across the island, causing significant
population declines (McCallum 2008; McCallum et al. 2009).
DFT2 was discovered in 2014 and is currently restricted to a
small region of southeastern Tasmania (Pye et al. 2016).
Although comparatively little is known about DFT2 relative
to DFT1, the tumors are histologically, cytogenetically, and
genetically distinct despite gross morphological similarities
and are of independent origin (Pye et al. 2016; Stammnitz
et al. 2018).
Low devil genetic diversity (Miller et al. 2011; Hendricks
et al. 2017) and silencing of cell surface MHC molecules by
DFTD have putatively led to universal susceptibility and
100% mortality (Siddle et al. 2013). Yet all devil populations
continue to persist, suggesting that devils are responding to
DFTD (Jones et al. 2008; Lazenby et al. 2018). Recent
work in devils has found evidence of an immune response
to DFT1 (Pye et al. 2016), rapid evolution in genes related
to immune function and cancer risk following disease ar-
rival (Epstein et al. 2016), and few loci of large-effect un-
derlying disease-related phenotypes such as survival
following infection (Margres et al. 2018). Collectively,
these studies suggest the evolution of resistance and/or
tolerance to DFT1 in devils.
Recently, natural (i.e., unmedicated) tumor regression has
been detected in northwestern Tasmania (fig. 1; Pye et al.
2016; Wright et al. 2017). In these cases, devils with previ-
ously confirmed DFT1 were recaptured with either substantial
tumor shrinkage or entire disappearance of the tumor. Recent
work on CTVT regression (which, unlike in DFT1, is common)
has shown that host response plays a critical role in triggering
tumor regression (Frampton et al. 2018), suggesting that
DFT1 regression may also be driven by the devil immune sys-
tem. Wright et al. (2017) recently used whole-genome se-
quencing (WGS) and a genome-wide association (GWA)
approach to compare the genomes of six devils with
regressed tumors to the genomes of five devils with
nonregressed tumors. Despite significant statistical limita-
tions due to unavoidable sample size limitations (i.e., re-
gression is a rare, novel phenotype), Wright et al. (2017)
found evidence that loci involved with angiogenesis may
be associated with tumor regression. Although GWA
methods are a classical approach for identifying the ge-
nomic basis of variation in disease phenotypes, these
studies often require several thousand samples to attain
appropriate statistical power (Yang et al. 2015). Even for
species such as S. harrisii with small populations and
strong linkage disequilibrium (Epstein et al. 2016), many
more than a dozen samples are needed to reliably detect
variants of an appreciable effect in a case–control GWA
framework (Kardos et al. 2016; Margres et al. 2018).
Furthermore, Frampton et al. (2018) showed that tumor
regression in CTVT is polygenic and driven by several
genes, most notably cyto/chemokines involved with in-
flammation and interferon signaling. Wright et al.
Fig. 1.—Sampling of Sarcophilus harrisii. We collected tissue samples
from seven individuals that underwent tumor regression and three indi-
viduals that did not for whole-genome sequencing. Sampling region as
well as the sites of discovery (i.e., putative sites of origin) for DFT1 and
DFT2 are indicated in the inset.
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(2017), however, looked at significant associations for in-
dividual SNPs and indels. Although methods for incorpo-
rating gene set analyses and other polygenic approaches
into a GWA framework exist (Mooney et al. 2014), these
models also require many more than a dozen samples
(Chatterjee et al. 2013), thus precluding their use for in-
vestigating the genetic basis of tumor regression in
Tasmanian devils.
We therefore used WGS and FST-based approaches to
compare the genomes of seven individuals that underwent
tumor regression (i.e., cases) with those of three infected
individuals that did not (i.e., controls) to identify the genetic/
polygenic basis of natural tumor regression in Tasmanian dev-
ils. We approximately doubled the genome coverage of
Wright et al. (2017; 10–15 to 20–30) and genotyped
SNPs, indels, and larger structural variants (SVs) for each indi-
vidual; the latter were not previously investigated. Genomic
instability has repeatedly been shown to be important in
many human cancers (e.g., Hartwell 1992; Akagi et al.
2014) as well as in DFT1 and DFT2 (Deakin et al. 2012;
Murchison et al. 2012; Pye et al. 2016; Stammnitz et al.
2018). SVs in the human genome, however, can also be
associated with disease susceptibility (Tuzun et al. 2005;
Manolio et al. 2009) and may have a higher probability,
relative to SNPs, of affecting phenotypes (Cooper et al.
2007). We used these three classes of genetic variation to
characterize the polygenic basis of tumor regression by
identifying large candidate genomic regions and particu-
lar biological pathways that differentiated cases and con-
trols. Previous work suggested that loci involved with
angiogenesis (Wright et al. 2017), chemokine signaling
(Frampton et al. 2018), and cell adhesion (Epstein et al.
2016; Margres et al. 2018) may be important to tumor
regression/devil response to DFT1. Frampton et al. (2018)
also showed that the differential expression of key genes
leads to CTVT regression, and the predominance of ex-
pression differentiation underlying rapid, adaptive
responses has been documented in humans (Fraser
2013) and other systems (Konczal et al. 2015; Margres
et al. 2017). We therefore predicted that loci involved
with one or more of these pathways would be highly dif-
ferentiated between cases and controls, and that this dif-
ferentiation would be biased toward putative regulatory
rather than protein-coding regions. Although transcrip-
tomics is most often used to identify differential gene ex-
pression and regulatory variation (Morandin et al. 2016;
Breschi et al. 2017; Rokyta et al. 2017), serial sampling of
devil tissue pre and postregression was not feasible due to
the stochasticity of recapture events. We therefore iden-
tified significantly conserved noncoding sequences across
devils and other mammals as putative regulatory ele-
ments. We then mapped highly differentiated variants
to these regions to identify putative regulatory variation
underlying the regression phenotype.
Materials and Methods
Sampling and WGS
We sequenced the genomes of ten S. harrisii from northwest-
ern Tasmania (fig. 1). All devils were confirmed to have DFT1.
Seven of these individuals (six females, one male) exhibited
tumor regression (i.e., cases), and three individuals (one fe-
male, two males) did not (i.e., controls). Individuals were clas-
sified as possessing the regression phenotype if tumor volume
decreased15% of the initial tumor volume upon recapture.
Genomic DNA was extracted from ear biopsies. Whole-
genomes for each individual were sequenced 150 bp
paired-end on an Illumina HiSeq X platform to 30 cover-
age. Sequencing was performed at the Northwest Genomics
Center at the University of Washington (Seattle, Washington,
USA) and GENEWIZ (South Plainfield, New Jersey, USA). All
raw data were deposited in the Sequence Read Archive (SRA)
under BioProject PRJNA450403 and accessions SRR7015138,
SRR7015139, SRR7015141–SRR7015147, and SRR7015149.
Alignments and Variant Calling
We merged raw reads with FLASH2 (Magnoc and Salzberg
2011) and trimmed with Sickle (Joshi and Fass 2011). We then
aligned merged and unmerged reads to the reference ge-
nome (downloaded from Ensembl January 2016; Murchison
et al. 2012) using the BWA-MEM algorithm (Li and Durbin
2009). We identified SNPs and indels using HaplotypeCaller in
GATK (McKenna et al. 2010; DePristo et al. 2011) as previ-
ously described (Margres et al. 2017). We identified
2,822,764 and 1,194,776 raw SNPs and indels, respectively.
Raw variants were filtered in VCFtools (Danecek et al. 2011)
and were required to possess a minimum depth value of 15 as
well as a minimum genotype quality of 60. Following filtering,
the final SNP and indel data sets contained 1, 271, 835 and
281, 046 variants, respectively.
Identifying the Genomic Basis of Tumor Regression
We used the Genotype Phenotype Association Toolkit
(GPATþþ) from the vcflib package (Garrison 2012) as previ-
ously described (Domyan et al. 2016) to identify case–control
genomic differentiation. To avoid the high false positive rate
inherent to any FST-based outlier detection approach using
small sample sizes (Lotterhos and Whitlock 2015; Verity
et al. 2017), we used the segmentFst function from
GPATþþ to identify candidate genomic regions with contin-
uous, elevated FST values relative to the surrounding genome
(Domyan et al. 2016); we were much less likely to find highly
differentiated, large genomic regions encompassing many
variants through sampling error than single variants spread
across the genome. We used this approach to identify candi-
date genomic regions using the SNP and indel data indepen-
dently. Differentiation was visualized as a Manhattan plot
using the pFst function from GPATþþ (Garrison 2012). pFst
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uses a likelihood ratio test for allele frequency differences
between case–control groups while incorporating geno-
type likelihood information to account for potential se-
quencing error. SNPs and indels in candidate genomic
regions were characterized using variant effect predictor
(VEP; McLaren et al. 2016) and the reference genome
(downloaded from Ensembl January 2016; Murchison
et al. 2012). Each variant was classified as intergenic,
intronic, synonymous, nonsynonymous, being in an
untranslated region (UTR), or upstream or downstream
of a particular gene (i.e., 5 kb of the coding sequence).
We used GeneCards (www.genecards.org; Stelzer et al.
2016) to identify putative gene functions.
Identifying Structural Variation
We used Manta (Chen et al. 2016) to identify SVs in the ten
individual genomes. Manta uses paired and split-read evi-
dence to identify large indels, inversions, duplications, and
translocations. We ran a joint diploid sample analysis across
all individuals and identified 79,453 variants that passed de-
fault Manta filters. We then calculated Weir and Cockerham’s
FST (h; Weir and Cockerham 1984) to compare differentiation
between cases and controls for each variant. Because the
reference genome has only been assembled into 36,000
scaffolds (Murchison et al. 2012) and contains many missing
base pairs, more than half of the identified large indels
mapped to these regions and were, therefore, false positives.
We manually removed variants that mapped to regions of the
reference genome with50% N’s. We then took the remain-
ing top 0.1% of SVs (segmentFst did not identify any differ-
entiated genomic regions in this data set; data not shown)
and required a minimum phred-scaled quality score of 999.
This conservative approach identified 35 top SVs that passed
all filters.
Detecting Polygenic Selection
Because conventional methods such as integrated haplotype
score and derived intra-allelic nucleotide diversity have little
power to detect signatures of polygenic adaptation (i.e., small
allele frequency changes at many loci; Fagny et al. 2014), we
used Weir and Cockerham’s FST (h; Weir and Cockerham
1984) to compare differentiation between cases and controls
for six pathways (Power et al. 2017) relevant to cancer risk
and DFT1 response. We used one-sided Mann–Whitney U
tests to compare the level of case–control differentiation in
a given biological pathway to that of the rest of the genome
as previously described (Hsieh et al. 2016). Pathways exhibit-
ing greater differentiation than the genomic background may
be evolving under positive selection. We examined six biolog-
ical pathways previously shown to be associated with DFTD
response and/or cancer-related traits: Cell adhesion (Epstein
et al. 2016; Margres et al. 2018; n¼ 2442 genes), apoptosis
(n¼ 115; Epstein et al. 2016), cancer (n¼ 229; Rosenberg
et al. 2008), graft-versus-host (n¼ 13; Rosenberg et al.
2008), chemokine signaling (n¼ 79; Frampton et al. 2018),
and vascular endothelial growth factor signaling (n¼ 40;
Wright et al. 2017). Genes for each pathway were identified
in the Kyoto Encyclopedia of Genes and Genomes (KEGG;
Kanehisa and Goto 2000). All variants within 5 kb of the
coding-region of a gene were listed as a pathway variant.
SNPs and indels were analyzed independently. All genes
and pathways are provided in supplementary table S1,
Supplementary Material online.
Identifying Regulatory Regions from Whole-Genome
Sequences
To determine if candidate variants occurred in putative regu-
latory regions, we used gVISTA (Couronne et al. 2003) and
RankVISTA to identify conserved noncoding sequences (CNS)
across devils and humans. RankVISTA uses the Gumby algo-
rithm to estimate neutral evolutionary rates from nonexonic
regions in the alignment and identify statistically significant
segments that evolve more slowly than the background; phy-
logenetically weighted log-odds conservation scores of con-
served segments are translated to P-values using Karlin-
Altschul statistics (Martin 2004). The human genome (NCBI
v36.1, hg18, March 2006) was used as the reference for all
analyses. Identified CNS represent putative regulatory ele-
ments. We used a RankVISTA threshold of 0.5, a calculation
window of 100 bp, and limited these comparisons to the can-
didate genomic regions identified in our segmentFst analyses
described above. Candidate genomic regions that occurred
on scaffolds that did not contain annotated coding sequences
were excluded. For the shared SNP/indel candidate regions,
we took the earliest starting and latest stopping positions to
analyze the largest possible region. Because gVISTA cannot
analyze sequences >300 kb, we cut the larger genomic
regions into 300 kb blocks for these analyses. Significantly
conserved intronic and intergenic sequences were identified
as putative regulatory elements. Results were visualized in
VISTA (Dubchak et al. 2000; Mayor et al. 2000; Frazer et al.
2004) using six nondevil mammal genomes: Humans, mouse,
rat, dog, horse, and rhesus monkey. SNPs and indels were
then mapped to the identified CNS and annotated as putative
regulatory variants.
Results
Candidate Genomic Regions Underlying Tumor Regression
in Tasmanian Devils
We identified 11 highly differentiated genomic regions be-
tween cases and controls using the SNP data (fig. 2A).
These candidate regions occurred on ten scaffolds across 5
chromosomes and contained 22 annotated genes, 10 of
which had a putative immune and/or cancer-related function
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(table 1). Chromosome 6 and the X chromosome did not
possess any candidate regions.
We identified three highly differentiated genomic regions
between cases and controls using the indel data (fig. 2B).
These candidate regions occurred on three scaffolds across
chromosomes 3 and 5. All three candidate regions occurred
on scaffolds also identified in the SNP-based analysis. The SNP
candidate genomic region on chromosome 3 was completely
encompassed by the larger indel candidate region. The can-
didate indel region on chromosome 5 scaffold GL861622 was
completely encompassed by the larger SNP candidate region,
and the indel region on chromosome 5 scaffold GL861682
overlapped both candidate SNP regions identified on this scaf-
fold (fig. 2A and B; tables 1 and 2). The 3 candidate indel
regions contained 12 annotated genes, 7 of which had a
putative immune and/or cancer-related function (table 2).
All seven genes in the candidate indel regions on chromo-
some 5 were identified in the SNP-based analysis, but four
of the five genes identified in the candidate indel region on
chromosome 3 were not identified in the SNP-based analysis
(only MED12L was shared across the SNP and indel candidate
regions on chromosome 3; tables 1 and 2). Three of the four
genes identified only in the candidate indel region on chro-
mosome 3 had a putative immune and/or cancer-related
function (table 2).
Candidate SNPs Underlying Tumor Regression in
Tasmanian Devils
We identified 1148 SNPs in the 11 SNP-based candidate ge-
nomic regions described above (supplementary table S2,
Supplementary Material online), 585 of which we considered
highly differentiated (FST  0:500). Most of the highly differ-
entiated SNPs were intergenic (69.7%) and intronic (26.8%;
fig. 3A and table 1). Nineteen (3.3%) were up or down-
stream of a coding-region, a single highly differentiated SNP
was synonymous, and no nonsynonymous candidates were
identified (fig. 3A and table 1).
Forty-nine candidate SNPs occurred in or near loci with
putative cancer-related functions (table 1). We identified
two highly differentiated SNPs in the introns of WDR48
(0:560  FST  0:577), a putative tumor suppressor, and
Fig. 2.—Manhattan plots showing differentiation between cases and controls for (A) SNPs, (B) indels, and (C) structural variants. Blue points in (A) and
(B) indicate scaffolds that were identified as highly differentiated candidate genomic regions by segmentFst. The three candidate indel scaffolds in (B) are the
same scaffolds as in (A). Because the x axis is variant index rather than true genomic position (i.e., the 36,000 scaffolds of the reference genome
makes robust physical mapping problematic), the scaffolds only appear slightly shifted. (C) Blue points indicate empirical outliers that passed all
filters (see Materials and Methods). Green points indicate empirical outliers that did not pass all filters. The y axis in all panels represents the
negative log of the pFst statistic.
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Table 1
Candidate Genomic Regions Identified in the SNP-Based segmentFst Analysis with Corresponding Genes and Candidate SNPs
Chromsome Scaffold Start–End Gene Putative Function Candidate SNPs
1 GL834900 59090–264617 Protein phosphatase 2, regulatory
subunit B, delta (PPP2R2D)a
Cell growth/division control;
Activated TLR4 signalinga
–
BCL2/adenovirus E1B 19 kDa inter-
acting protein 3 (BNIP3)a
Apoptosis and authophagya –
Janus kinase and microtubule inter-
acting protein 3 (JAKMIP3)
Microtubule and kinase
binding
13 intronic
2 GL841602 886632–992998 Xylulokinase (XYLB) Metabolism 8 intronic
1 downstream
2 GL841626 476121–923043 Sodium channel, voltage-gated, type
XI, alpha subunit (SCN11A)
Action potential and pain
signaling
4 upstream
WD repeat domain 48 (WDR48)a Deubiquitinating complex
regulator; Potential tumor
suppressora
2 intronic
Golgi reassembly stacking protein
1 (GORASP1)
Protein sorting and
modiﬁcation
1 upstream
Tetratricopeptide repeat domain
21A (TTC21A)
Protein localization –
Xin actin-binding repeat containing
1 (XIRP1)a
Cellular junction function;
leukemia candidate genea
–
Solute carrier family 22, member
14 (SLC22A14)
Molecule transport –
Solute carrier family 22, member
13 (SLC22A13)
Molecular transport and
metabolism
–
Oxidative stress responsive
1 (OXSR1)a
Kinase response to environ-
mental stressa
–
3 GL849905 3117969–3162680 Mediator complex subunit
12-like (MED12L)
Transcriptional coactivation –
4 GL856968 1213224–1266653 – – –
5 GL861622 8458–1345777 Lymphoid-restricted membrane
protein (LRMP)a
Peptide delivery to MHC
class I; related to b-cell
lymphomasa
–
Cancer susceptibility candidate
1 (CASC1)a
Microtubule and tubulin
binding; related to respira-
tory neoplasmsa
–
LYR motif containing 5 (LYRM5) Protein synthesis –
Kirsten rat sarcoma viral oncogene
homolog (KRAS)a
Member of small GTPase su-
perfamily; implicated in
multiple carcinomasa
1 intronic
Lamin tail domain containing
1 (LMNTD1)a
Structural activity; related to
respiratory neoplasmsa
30 intronic
4 upstream
4 downstream
Ras association domain family
member 8 (RASSF8)a
Tumor suppressor protein;
epithelial cell migrationa
–
Sarcospan (SSPN) Structural support –
5 GL861682 1183188–1317129 Glutamate decarboxylase 2 (GAD2) L-glutamic acid catalysis 87 intronic
2 upstream
1 synonymous
5 GL861682 1500464–1544340 Myosin IIIA (MYO3A)a Hearing; associated with
bladder/colon cancera
7 intronic
1 upstream
5 GL861847 655–43394 – – –
5 GL862178 7209–28728 ENSSHAG00000000783 Unannotated coding
sequence
9 intronic
2 downstream
5 GL862286 963–11539 – – –
aPutative immune or cancer-related function. Candidate SNPs were variants with FST  0:5.
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a top SNP in the intron of KRAS (FST¼0.765), a gene im-
plicated in multiple carcinomas. We also identified 38
highly differentiated SNPs (0:566  FST  0:790) in or
near LMNTD1 and eight candidate SNPs
(0:500  FST  0:536) in or near MYO3A. LMNTD1 is
related to respiratory neoplasms, and although MYO3A
primarily functions in hearing, modifications in MYO3A
were found to be associated with bladder and colon can-
cer (see Discussion; Lascorz et al. 2010; Chung et al.
2011).
Table 2
Candidate Genomic Regions Identified in the Indel-Based segmentFst Analysis with Corresponding Genes and Candidate Indels
Chromsome Scaffold Start–End Gene Putative Function Candidate Indels
3 GL849905 2931754–3563755 MED12L Transcriptional coactivation 6 intronic
1 upstream
4 intronicb
G protein-coupled receptor
87 (GPR87)a
Regulated by p53; overexpressed in
carcinomasa
1 intronicb
3 downstreamb
Purinergic receptor P2Y,
G-protein coupled,
14 (P2RY14)a
Receptor activity; immune and neu-
roimmune functiona
–
G protein-coupled receptor
171 (GPR171)
Ligand-binding receptor –
Siah E3 ubiquitin protein li-
gase 2 (SIAH2)a
Hypoxia response; involved in apo-
ptosis and tumor suppressiona
–
5 GL861622 159894–1238762 CASC1a Microtubule and tubulin binding;
related to respiratory neoplasmsa
1 intronic
LYRM5 Protein synthesis –
KRASa Small GTPase superfamily member;
implicated in multiple carcinomasa
–
LMNTD1a Structural activity; related to respi-
ratory neoplasmsa
7 intronic
1 upstream
1 downstream
RASSF8a Tumor suppressor protein; epithelial
cell migrationa
1 intronic
5 GL861682 1186331–1550521 GAD2 L-glutamic acid catalysis 11 intronic
MYO3Aa Hearing; associated with bladder/co-
lon cancera
21 intronic
1 upstream
aPutative immune or cancer-related function.
bIndels found in overlapping open-reading frames and, therefore, with ambiguous designations. Candidate indels were variants with FST  0:5. Abbreviated gene names
were deﬁned in table 1.
UTR 0 %
Syn 0.2%
Nonsyn 0 %
Upstream 2.1%
Downstream 1.2%
Intergenic 69.7%
Intronic 26.8%
UTR 0%
Syn 0%
Nonsyn 0%
Upstream 2.3%
Downstream 0.8%
Intergenic 60.2%
Intronic 36.7%
A B
Fig. 3.—Pie charts depicting the relative frequencies of different mutational classes among the most differentiated (A) SNPs (n¼585) and (B) indels
(n¼128) in the candidate genomic regions from figure 2. Nonsyn, nonsynonymous; Syn, synonymous; UTR, untranslated region.
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Candidate Indels Underlying Tumor Regression in
Tasmanian Devils
We identified 197 indels in the 3 indel-based candidate ge-
nomic regions (supplementary table S3, Supplementary
Material online), 132 of which were highly differentiated
(FST  0:500). Excluding the four ambiguous highly differen-
tiated indels identified in the overlapping gene region on
chromosome 3 (see below), most of the highly differentiated
indels were intergenic (60.2%) and intronic (36.7%; fig. 3B
and table 2). Four indels (3.1%) were up or downstream of
a coding-region. As expected, no indels were identified in the
coding-regions or UTRs of genes (fig. 3B and table 2).
For the candidate region on chromosome 3 (fig. 2B and ta-
ble 2), we identified four variants with ambiguous designations
because MED12L (scaffold position 2786476–3136515) and
GPR87 (scaffold position 2912235–2934071) are overlapping
genes. Overlapping genes have been documented in vertebrate
genomes, including humans and other mammals (e.g.,
Makalowska et al. 2005). Based on the annotation of the refer-
ence S. harrisii genome (downloaded from Ensembl January
2016; Murchison et al. 2012),GPR87 is nested withinMED12L.
We identified one highly differentiated variant (FST¼0.644) in
intronic regions of both genes as well as three variants that oc-
curred in an intronic region of MED12L and downstream of
GPR87(0:571  FST  0:644).MED12Lfunctionsintranscrip-
tional coactivation, andGPR87 is regulated by p53 (table 2).
Several other candidate indels also occurred in or near loci
with putative cancer-related functions (table 2). We identified
seven intronic candidates (0:804  FST  0:864) as well as
individual up- (FST¼0.884) and downstream candidates
(FST¼0.831) for LMNTD1. We also identified candidate indels
in the introns of RASSF8 (FST¼0.686) and CASC1 (FST¼0.556).
RASSF8 is a putative tumor suppressor, and CASC1 has also
been associated with neoplasms, similar to LMNTD1 (table 2).
Twenty-one intronic (0:516  FST  0:703) and an up-
stream candidate indel (FST¼0.703) were found for MYO3A
(table 2); MYO3A also possessed several candidate SNPs
(table 1) and has been implicated in cancer susceptibility
(Lascorz et al. 2010; Chung et al. 2011).
Candidate SVs Underlying Tumor Regression in Tasmanian
Devils
We identified 35 highly differentiated putative SVs that
passed all filters (fig. 2C). Of these 35 candidate SVs, 21
were intergenic, 11 were found in the introns of 10 genes,
1 variant was upstream of a gene, and 2 variants were down-
stream of a single gene. Of the 14 variants in or near genes,
we identified 6 insertions (58–584 bp), 2 deletions (95–
614 bp), and 6 putative translocations (table 3). Both deletions
and all but one insertion occurred in introns; one insertion was
upstream of a coding-sequence. Of the six putative translo-
cations, four occurred in introns and two occurred in down-
stream regions, although both putative downstream
translocations also involved introns of another gene (i.e., we
genotyped six highly differentiated translocations, but two
overlapped, leaving four candidate translocations; see below;
table 3).
Six of the 12 genes associated with a candidate SV were
implicated in immune-response and/or cancer-risk (table 3).
We identified insertions in the introns of CSRNP3, MAP3K5,
and SEC31A; the former two genes are involved with apo-
ptosis, and the latter is associated with inflammatory myofi-
broblastic tumors. We also found putative translocations
involving three candidate genes (table 3). We identified a pu-
tative translocation between the intron of TRIM33, which is
involved with the ligation of E3 ubiquitin-protein and is related
to carcinomas, with an intergenic region on chromosome
three. We also identified two putative translocations between
the downstream regions of LMNTD1 and the intronic regions
of TNKS. LMNTD1 has been associated with respiratory neo-
plasms and was identified as a candidate gene in both the
SNP (table 1) and indel (table 2) analyses. TNKS is involved
with Wnt signaling and associated with various forms of hu-
man cancer (table 3).
Detecting the Polygenic Basis of the Regression Phenotype
FST distributions for all six biological pathways for SNPs
(0:19  P  1:00) and indels (0:83  P  1:00) were
nearly identical to that of the rest of the genome, indicating
an absence of detectable polygenic selection in these partic-
ular pathways (supplementary fig. S1, Supplementary
Material online).
Identification of Putative Regulatory Elements in the
Candidate Genomic Regions
We identified CNS in six of the seven candidate genomics
regions analyzed; the first candidate region on chromosome 2
(scaffoldGL841602)didnot returnamatch.Althoughweiden-
tified between 1 and 52 CNS per candidate genomic region,
only one candidate genomic region, scaffold GL861682 on
chromosome5,possessedvariants in the identifiedCNS(fig.4).
On chromosome 5 scaffold GL861682, we identified 23
conserved intronic sequences, all of which were introns for
MYO3A, and a single conserved intergenic sequence; these
regions were 102–541 bp and 67.5–85.4% similar at the se-
quence level. Two of the conserved MYO3A intronic sequen-
ces, which represent putative regulatory elements, possessed
SNPs that were highly differentiated between cases and con-
trols (fig. 4). The first candidate regulatory intronic region
(position 1438502–1438639, 73.6% similarity to the human
genome) possessed a highly differentiated SNP at position
1438555 (FST¼0.536). The second candidate regulatory
intronic region (position 1498234–1498453, 73.3% similarity
to the human genome) possessed two candidate SNPs at
positions 1498270 (FST¼0.536) and 1498411 (FST¼0.491).
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Discussion
We predicted that the genomic basis of tumor regression in
Tasmanian devils would be 1) polygenic; 2) involve specific
biological pathways related to cancer risk and DFT1 response;
and 3) be biased toward putative regulatory rather than
protein-coding regions. We found three highly differentiated
candidate genomic regions, indicating that the genomic basis
of tumor regression in Tasmanian devils was polygenic. We
did not detect signatures of polygenic selection in the six
pathways investigated, suggesting that the genetic basis of
tumor regression is either associated with the candidate
genomic regions discussed above and/or other biological
pathways. We identified putative regulatory variation in genes
related to immune response and/or cancer risk but no non-
synonymous variation, suggesting that natural DFT1 regres-
sion may be driven, at least in part, by differential host
expression of key candidate genes. We discuss each outcome
in detail below.
First, we identified three highly differentiated candidate
regions across chromosomes 3 and 5. Although not all var-
iants in these candidate regions were necessarily associated
with the regression phenotype and may simply be linked to
Table 3
Candidate Genes Identified in the Structural Variant Analysis
Chromsome Scaffold Position Type Gene Putative Function
2 GL841465 252851 58 bp insertion intron DTW domain containing 2
(DTWD2)
Mitochondrion protein
targeting
GL841584 1176582 95 bp deletion intron BMP binding endothelial regula-
tor (BMPER)
Bone morphogenetic protein
inhibition
3 GL849630 133609 584 bp insertion upstream Solute carrier family 38 member
11 (SLC38A11)
Amino acid transport
GL849631 677692 278 bp insertion intron Cysteine-serine-rich nuclear pro-
tein 3 (CSRNP3)a
Transcriptional activator regu-
lator; apoptosisa
4 GL856953 1140408 247 bp insertion intron Mitogen-activated protein ki-
nase kinase kinase 5
(MAP3K5)a
Apoptosis signal transductiona
GL856993 210323 Translocation of intron with
intergenic region on chro-
mosome 3 (GL849549)
Tripartite motif containing 33
(TRIM33)a
E3 ubiquitin-protein ligase;
related to carcinomasa
5 GL861591 1045356 614 bp deletion intron ENTH domain containing 1
(ENTHD1)
Unknown
GL861622 511673 Translocation of downstream
region with intron of
tankyrase (TNKS) on chro-
mosome 6 (see below)
LMNTD1a Structural activity; related to
respiratory neoplasmsa
511686 Translocation of downstream
region with intron of TNKS
on chromosome 6 (see
below)
LMNTD1a Structural activity; related to
respiratory neoplasmsa
GL861672 1578145 69 bp insertion intron GTP binding protein 4 (GTPBP4) Cell signaling
6 GL864736 1234425 Translocation of intron with
downstream region of
LMNTD1on chromosome5
(see above)
TNKSa Wnt signaling; target of cancer
treatmenta
1234867 Translocation of intron with
downstream region of
LMNTD1on chromosome5
(see above)
TNKSa Wnt signaling; target of cancer
treatmenta
GL864753 78910 395 bp insertion intron SEC31 homolog A (SEC31A)a Vesicle budding; related to in-
ﬂammatory myoﬁbroblastic
tumorsa
X GL867607 3118283 Translocation of intron with
intergenic region on chro-
mosome 1 (GL835007)
Dachshund family transcription
factor 2 (DACH2)
Transcription factor
aPutative immune or cancer-related function. Abbreviated gene names were deﬁned in tables 1 and 2.
Margres et al. GBE
3020 Genome Biol. Evol. 10(11):3012–3025 doi:10.1093/gbe/evy229 Advance Access publication October 13, 2018
one or a few large-effect variants, the strong signal of differ-
entiation across multiple genomic regions suggested that
the regression phenotype was indeed polygenic. These
regions were independently identified in the SNP- and
indel-based analyses and contained candidate genes
such as GPR87, CASC1, KRAS, RASSF8, and LMNTD1, all
of which contained one or more candidate variants.
LMNTD1 was identified as a candidate gene in the SNP-,
indel-, and SV-based analyses, although the SV-based
results must be interpreted with caution; the fragmented
state of the reference genome (i.e., 36,000 scaffolds)
made interpretation difficult.
Second, we did not detect signatures of polygenic selection
in the six pathways investigated. Given that tumor regressions
were first detected in 2009 (Pye et al. 2016; Wright et al.
2017) and that first-step mutations are often of large-effect
(Rokyta et al. 2005), minor allele frequency changes at many
loci may not have had enough time to occur (e.g., 4–5
Reference genome: Chromosome 10:Human 2006 26,305,496-26,425,631
100%
50%
100%
50%
100%
50%
MYO3A
100%
50%
100%
50%
100%
50%
Annotations:
Exon
UTR
CNS
Gene
26,306k 26,326k 26,346k 26,366k 26,386k 26,406k
Mouse 2007
Rat 2004
Dog 2005
Horse 2007
Macaque
    2006
Si
m
ila
rit
y
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m
ila
rit
y
Si
m
ila
rit
y
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m
ila
rit
y
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m
ila
rit
y
Si
m
ila
rit
y
Devil 2012
26,305,502 26,305,582 26,305,662 26,305,742 26,305,822
A
B
26,377,051 26,377,091 26,377,131 26,377,171
C
* * *
Fig. 4.—VISTA plot showing conserved sequences across devils and six other mammals for a candidate genomic region containing MYO3A. (A) We
plotted 1,400,000–1,500,000 on devil chromosome 5 scaffold GL861682. Two conserved intronic sequences (B and C), indicated by the red boxes in (A),
possessed candidate SNPs that were highly differentiated (FST  0:491) between cases and controls, suggesting that these SNPs may lead to regulatory
variation inMYO3A. Genomic position in the reference human genome is listed on the x axis in all panels. Percent similarity is shown on the y axis where the
blue line indicates 70% identity in all panels. Asterisks represent approximate location of candidate SNPs. CNS, conserved noncoding sequence; UTR,
untranslated region.
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generations assuming a 2-year generation time; McCallum
et al. 2009; Hamede et al. 2015). The polygenic basis of
DFT1 regression may therefore be in the form of a few,
large-effect variants rather than many variants of small-
effect, consistent with other work investigating the genetic
basis of DFT1-related phenotypes in devils (e.g., survival fol-
lowing infection; Margres et al. 2018).
Third, none of the candidate variants were nonsynony-
mous, and only a single candidate synonymous SNP was iden-
tified, suggesting that differential expression of key candidate
genes in devils may play a role in tumor regression. Indeed,
Wright et al. (2017) did not find any candidate SNPs in
coding-sequences using GWA approaches investigating the
same trait, and CTVT regression in dogs also appears to be
driven, at least in part, by differential gene expression
(Frampton et al. 2018). Noncoding variation has also repeat-
edly been linked to tumorigenesis and other diseases in
humans (e.g., Mathelier et al. 2015). Bias toward differential
expression rather than nonsynonymous variation, however, is
not specific to tumor regression or cancer-related phe-
notypes. Several studies have suggested that adaptive
expression differentiation may be more likely than adap-
tive changes to coding regions, at least for rapid adap-
tation in complex phenotypes, because more mutational
mechanisms exist for altering expression levels than for
protein-coding sequences (Fraser 2013; Konczal et al.
2015; Margres et al. 2017). Our results are consistent
with these expectations.
We also found three candidate SNPs in two significantly
conserved intronic sequences inMYO3A. Introns can function
as regulatory elements (e.g., Majewski and Ott 2002; Wei
et al. 2006), and the conservation of these intronic regions
across 160 Myr of evolution (marsupial-placental split; Luo
et al. 2011) indicated that these sequences may have an im-
portant regulatory function. These three candidate SNPs,
therefore, may lead to differential expression of MYO3A be-
tween cases and controls. Although MYO3A primarily func-
tions in transferase/kinase activity and plays a key role in
hearing in humans, MYO3A is highly methylated in bladder
tumors (Chung et al. 2011). A GWA study also found that an
SNP in the intron ofMYO3Awas associated with an increased
risk for colon cancer in humans (Lascorz et al. 2010), similar to
our results (although the candidate colon cancer SNP,
rs11014993, occurred in a different intron). Future transcrip-
tomic and functional genomic studies of serially sampled dev-
ils with and without the regression phenotype are needed to
determine if MYO3A, along with the other candidate genes,
are differentially expressed to determine what role these
genes may have in tumor regression.
Despite substantial statistical limitations due to the rarity of
the regression phenotype and therefore unavoidable small
sample sizes, Wright et al. (2017) used a GWA framework
and found evidence that SNPs in the introns of loci involved
with angiogenesis, particularly PAX3, may be associated with
tumor regression. PAX3 occurs on chromosome 3 but on a
different scaffold than the candidate region we identified on
the same chromosome. We did identify variants in the introns
as well as up and downstream of PAX3, but none of these
variants were highly differentiated. The top variant for PAX3
was an intronic SNP (FST¼0.307), but mean FST for PAX3
intronic SNPs was 0.026 and all FST estimates for indels
near PAX3 were0. PAX3, however, is involved in angiogen-
esis through regulation of bone morphogenic proteins (BMP).
We found a 95-bp deletion in the intron of BMPER on chro-
mosome 2, indicating that angiogenesis may indeed play an
important role in natural tumor regression (although our poly-
genic selection analysis suggested otherwise).
Comparative oncology should lead to advances in both
human and animal health (Schiffman and Breen 2015), and
tumor regression is not specific to transmissible cancers.
Spontaneous tumor regression, albeit rare (1 in 60–
100,000 cases; Missotten et al. 2008), has been documented
in human cancers (Sengupta et al. 2010). One such cancer is
Merkel cell carcinoma (MCC), a rare type of skin cancer that
often appears on the face, head, or neck in the form of a
nodule (Goessling et al. 2002). MCC is of neuroendocrine
origin (Goessling et al. 2002) and may be associated with
Merkel cell polyomavirus, somewhat similar to DFT1’s neuro-
ectoderm/Schwann cell origin and transmissible nature
(Murchison et al. 2010). The first spontaneous regression of
MCC was documented in 1986 (O’Rourke and Bell 1986),
and regression has occurred at least 22 times since. The mech-
anism of MCC regression is unclear but may be driven by a T-
cell-mediated immune response (Connelly et al. 2000; Pang
et al. 2015).
Understanding the genetic basis of regression in DFT1 and
other nonhuman cancers may enable the identification of
general mechanisms underlying tumor regression in MCC
and other human cancers. Indeed, ethical considerations of-
ten preclude investigating natural, untreated tumor progres-
sion in human cancers, highlighting the importance of
comparative oncological studies investigating the genetic ba-
sis of general tumor phenotypes such as regression. The non-
linear relationship between genotype and cancer-related traits
has been labeled as one of the biggest challenges in biomed-
ical sciences (Katsios and Roukos 2010), and comparative on-
cology should advance our knowledge of cancer progression,
tumor regression, and cancer-normal cell interactions and co-
evolution (Schiffman and Breen 2015). We identified specific,
putative regulatory variants in or near genes related to im-
mune response and/or cancer risk that differentiated cases
from controls, indicating that natural tumor regression may
be driven, at least in part, by differential host expression of key
genes. Our results support the concept that host immune
response is necessary for triggering tumor regression
(Frampton et al. 2018), providing candidate genes and mech-
anisms that may translate to novel treatments in human and
nonhuman cancers.
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